FNDC1 Protein, Human, Recombinant (His)

一键复制产品信息

产品编号 TMPK-00994

Fibronectin type III domain‑containing protein 1 (FNDC1) is a protein that contains a major component of the structural domain of fibronectin.FNDC1 was highly upregulated and acted as an oncogene in BC. Therefore, targeting FNDC1 may be a potential strategy for the treatment of BC.

FNDC1 Protein, Human, Recombinant (His)

一键复制产品信息

产品编号 TMPK-00994

规格	价格	库存
5 μg	¥ 313	现货
10 μg	¥ 498	现货
20 μg	¥ 793	3日内发货
50 μg	¥ 1,580	3日内发货
100 μg	¥ 2,660	现货
200 μg	¥ 4,790	5日内发货
500 μg	¥ 10,600	5日内发货

大包装 & 定制

加入购物车

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

选择批次

资源下载

COA 重组蛋白用户指南

产品信息

生物活性	Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
产品描述	Fibronectin type III domain‑containing protein 1 (FNDC1) is a protein that contains a major component of the structural domain of fibronectin.FNDC1 was highly upregulated and acted as an oncogene in BC. Therefore, targeting FNDC1 may be a potential strategy for the treatment of BC.
种属	Human
表达系统	E. coli
标签	N-His
蛋白编号	Q4ZHG4-1
别名	MEL4B3,KIAA1866,FNDC2
蛋白构建	Ala33-Thr457
蛋白纯度	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
分子量	48.68 kDa (predicted). The protein migrates to 50-55 kDa based on Tris-Bis PAGE result.
内毒素	< 1 EU/μg by the LAL method.
蛋白性状	Solution
缓冲液	Supplied as 0.22 μm filtered solution in 20 mM PB, 500 mM NaCl, 10% Glycerol.
存储	It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景	Fibronectin type III domain‑containing protein 1 (FNDC1) is a protein that contains a major component of the structural domain of fibronectin.FNDC1 was highly upregulated and acted as an oncogene in BC. Therefore, targeting FNDC1 may be a potential strategy for the treatment of BC.